Last reviewed · How we verify
OD-PHOENIX
Data not available
OD-PHOENIX is a discontinued therapeutic candidate developed by TBF Genie Tissulaire. The drug entered clinical development with a total of 2 registered trials but did not advance to regulatory approval. No FDA label, EMA marketing authorization, or published clinical data are available in public databases. The discontinuation suggests either insufficient efficacy/safety signals, commercial viability concerns, or strategic portfolio decisions by the originating company. Without access to mechanism of action, indication focus, or clinical trial results, institutional assessment of this asset is severely limited. This profile reflects the scarcity of publicly available information on this withdrawn program.
At a glance
| Generic name | OD-PHOENIX |
|---|---|
| Also known as | Osteochondral allograft |
| Sponsor | TBF Genie Tissulaire |
| Drug class | Data not available |
| Target | Data not available |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
No mechanism of action data is available for OD-PHOENIX. The drug was discontinued before reaching regulatory approval or substantial public disclosure of its pharmacological properties. Without access to preclinical studies, IND applications, or clinical trial protocols, the molecular target, pathway modulation, and pharmacodynamic profile cannot be determined.
Approved indications
Pipeline indications
- Data not available — Data not available
Common side effects
Key clinical trials
- Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft (PHASE1, PHASE2)
- OD-PHOENIX in Talus Osteochondral Lesion (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OD-PHOENIX CI brief — competitive landscape report
- OD-PHOENIX updates RSS · CI watch RSS
- TBF Genie Tissulaire portfolio CI